HuGE Literature Finder
Records 1-12
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
British journal of clinical pharmacology 2020 May . Axelsen Lene Nygaard, Poggesi Italo, Rasschaert Freya, Perez Ruixo Juan Jose, Bruderer Shir |
Interaction among CYP2C8, GPIIIa and P2Y12 variants increase susceptibility to ischemic stroke in Chinese population.
Oncotarget 2017 Sep 8 (41): 70811-70820. Yi Xingyang, Lin Jing, Wang Yanfen, Zhou Ju, Zhou Qia |
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
Clinical and experimental hypertension (New York, N.Y. : 1993) 2017 May 1-6. Polonikov Alexey, Bykanova Marina, Ponomarenko Irina, Sirotina Svetlana, Bocharova Anna, Vagaytseva Kseniya, Stepanov Vadim, Churnosov Mikhail, Bushueva Olga, Solodilova Maria, Shvetsov Yaroslav, Ivanov Vladim |
Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients.
Biochemical genetics 2015 Sep . Tzveova Reni, Naydenova Galya, Yaneva Teodora, Dimitrov Georgi, Vandeva Silviya, Matrozova Yoanna, Pendicheva-Duhlenska Diana, Popov Ivan, Beltheva Olga, Naydenov Cyrill, Tarnovska-Kadreva Rumiana, Nachev Gencho, Mitev Vanio, Kaneva Rad |
CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke.
Gene 2015 Jul 565 (1): 85-9. Yi Xingyang, Zhang Biao, Wang Chun, Liao Duanxiu, Lin Jing, Chi Lif |
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Drug metabolism and disposition: the biological fate of chemicals 2013 Jan 41 (1): 224-9. Cabaleiro Teresa, Román Manuel, Ochoa Dolores, Talegón María, Prieto-Pérez Rocío, Wojnicz Aneta, López-Rodríguez Rosario, Novalbos Jesús, Abad-Santos Francis |
Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography.
Journal of clinical pharmacy and therapeutics 2010 Dec 35 (6): 723-8. Teh L K, Zahri M K, Zakaria Z A, Ismail R, Salleh M |
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort.
Pharmacogenomics 2010 Oct 11 (10): 1359-65. Haschke-Becher Elisabeth, Kirchheiner Julia, Trummer Olivia, Grünbacher Gerda, Kainz Alexander, Boehm Bernhard O, März Winfried, Renner Wilfri |
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
Pharmacogenomics 2008 Mar 9 (3): 277-88. Kirchheiner Julia, Meineke Ingolf, Fuhr Uwe, Rodríguez-Antona Cristina, Lebedeva Elena, Brockmöller Jürg |
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.
American journal of hypertension 2005 Oct 18 (10): 1276-81. Dreisbach Albert W, Japa Shanker, Sigel Aster, Parenti Melissa B, Hess Arthur E, Srinouanprachanh Sengkeo L, Rettie Allan E, Kim Helen, Farin Federico M, Hamm L Lee, Lertora Juan J |
Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.
Pharmacogenetics and genomics 2005 Jan 15 (1): 7-13. King Lorraine M, Gainer James V, David Gloria L, Dai Ding, Goldstein Joyce A, Brown Nancy J, Zeldin Darryl |
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.
Pharmacogenetics 2003 Dec 13 (12): 715-20. Yasar Umit, Bennet Anna M, Eliasson Erik, Lundgren Stefan, Wiman Björn, De Faire Ulf, Rane Ande |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: